BARRY MOZE - 04 Nov 2021 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role
EVP, Chief Admin. Officer
Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
04 Nov 2021
Net transactions value
-$7,385,652
Form type
4
Filing time
05 Nov 2021, 17:00:21 UTC
Previous filing
30 Jul 2021
Next filing
06 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Options Exercise $66,420 +3,000 +4% $22.14* 78,681 04 Nov 2021 Direct
transaction HZNP Ordinary Shares Options Exercise $5,232 +443 +0.56% $11.81* 79,124 04 Nov 2021 Direct
transaction HZNP Ordinary Shares Options Exercise $1,046,904 +72,300 +91% $14.48* 151,424 04 Nov 2021 Direct
transaction HZNP Ordinary Shares Sale $2,575,995 -23,382 -15% $110.17 128,042 04 Nov 2021 Direct F1, F2
transaction HZNP Ordinary Shares Sale $1,771,908 -15,856 -12% $111.75 112,186 04 Nov 2021 Direct F1, F3
transaction HZNP Ordinary Shares Sale $692,603 -6,151 -5.5% $112.60 106,035 04 Nov 2021 Direct F1, F4
transaction HZNP Ordinary Shares Sale $2,028,977 -17,867 -17% $113.56 88,168 04 Nov 2021 Direct F1, F5
transaction HZNP Ordinary Shares Sale $773,890 -6,763 -7.7% $114.43 81,405 04 Nov 2021 Direct F1, F6
transaction HZNP Ordinary Shares Sale $660,836 -5,724 -7% $115.45 75,681 04 Nov 2021 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 -3,000 -1.8% $0.000000 162,181 04 Nov 2021 Ordinary Shares 3,000 $22.14 Direct F8
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 -443 -100% $0.000000* 0 04 Nov 2021 Ordinary Shares 443 $11.81 Direct F8
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 -72,300 -100% $0.000000* 0 04 Nov 2021 Ordinary Shares 72,300 $14.48 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.985 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.10 to $112.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.12 to $113.085 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.14 to $114.135 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.14 to $115.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.15 to $115.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The stock option is fully vested and exercisable.